| 李囡,范洋,翟士桢,周妮娜,于江媛,张岩,赵伟,杨志.18F-FDG PET/CT在原发乳腺癌患者治疗后随访中的应用[J].中国医学影像技术,2016,32(6):890~895 |
| 18F-FDG PET/CT在原发乳腺癌患者治疗后随访中的应用 |
| Application of 18F-FDG PET/CT in follow-up of primary breast cancer patients after treatment |
| 投稿时间：2015-10-19 修订日期：2015-12-14 |
| DOI：10.13929/j.1003-3289.2016.06.019 |
| 中文关键词: 乳腺肿瘤 复发 转移 18F氟脱氧葡萄糖 体层摄影术,发射型计算机 肿瘤标志物 |
| 英文关键词:Breast neoplasms Recurrence Metastasis Fluorodeoxyglucose F18 Tomography, emission-computed Tumor marker |
| 基金项目: |
|
| 摘要点击次数: 2696 |
| 全文下载次数: 764 |
| 中文摘要: |
| 目的 探讨18F-FDG PET/CT显像在原发乳腺癌治疗后随访中的作用。方法 收集原发乳腺癌治疗后患者174例,均接受18F-FDG PET/CT检查,由3名有多年诊断经验的医师独立阅片,以病理结果或随访1年结果为诊断标准。结果 174例患者中确诊复发转移72例,无复发转移64例,第二原发癌38例。18F-FDG PET/CT显像阳性者116例(复发转移69例、第二原发癌38例、假阳性9例),显像阴性者58例(无复发转移55例,假阴性病例3例)。18F-FDG PET/CT显像与血清肿瘤标志物的诊断效能分别为:灵敏度97.91% vs 72.73%,特异度85.94% vs 57.81%,准确率93.10% vs 67.24%,假阴性率2.73% vs 27.27%,假阳性率14.06% vs 42.19%,阳性预测值92.24% vs 74.77%,阴性预测值94.83% vs 55.22%,两者联合有助于提高阳性预测值和阴性预测值。患者的年龄、临床分期、治疗方法、18F-FDG PET/CT显像结果和血清肿瘤标志物情况是其病理/随访结果的影响因素(P<0.05),而患者的性别、原发病变部位、ER、PR、Her2的表达情况不是其病理/随访结果的影响因素(P>0.05)。结论 18F-FDG PET/CT显像可以较为准确地诊断或排除乳腺癌治疗后复发转移,还可帮助发现第二原发癌,具有较好的临床应用价值。 |
| 英文摘要: |
| Objective To explore the value of 18F-FDG PET/CT in diagnosis of recurrence and metastasis in the follow-up of primary breast cancer patients. Methods 18F-FDG PET/CT images of 174 breast cancer patients who underwent surgery with or without chemotherapy or radiotherapy were retrospectively reviewed. Diagnoses were made by three experienced nuclear medicine doctors and the diagnostic standard was the results of either pathology or one year follow-up. Results Of all 174 cases, there were 72 cases of local recurrence or metastasis, 64 cases without recurrence and 38 cases of second primary tumor cases. 18F-FDG PET/CT imaging was positive in 116 cases (69 cases of recurrence or metastasis, 38 cases of second primary tumor and 9 false positive cases), negative in 58 cases (55 cases with no recurrence and metastasis, 3 false negative cases). The diagnostic efficiency of 18F-FDG PET/CT and serum tumor maker were 97.91% vs 72.73% in sensitivity, 85.94% vs 57.81% in specificity, 93.10% vs 67.24% in accuracy, 2.73% vs 27.27% in false negative rate, 14.06% vs 42.19% in false positive rate, 92.24% vs 74.77% in positive predictive value (PPV), and 94.83% vs 55.22% in negative predictive value (NPV). The combination of these two methods could improve PPV and NPV. Age, clinical stage, treatment method, 18F-FDG PET/CT and serum tumor maker were predictors of follow-up results (P<0.05), while gender, primary tumor site, ER, PR, Her2 were not (P>0.05). Conclusion 18F-FDG PET/CT can be used to identify/rule out recurrence and metastasis or suggest second primary tumor in the follow up of breast cancer patients. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
